Neurosteroid biosynthetic pathway changes in substantia nigra and caudate nucleus in Parkinson's disease.
There is emerging evidence from animal studies for a neuroprotective role of sex steroids in neurodegenerative diseases, but studies in human brain are lacking. We have carried out an extensive study of the neurosteroid biosynthetic pathways in substantia nigra (SN), caudate nucleus (CN) and putamen (PU) of 7 Parkinson's disease (PD) patients and 7 matched controls. The mRNA levels of 37 genes including neurosteroid biosynthetic enzymes, hormone receptors and the neurosteroid-modulated gamma-amino-butyric acid -A (GABA-A) receptor subunits were analyzed by quantitative PCR (qPCR). In the SN, we found downregulation of 5alpha-reductase type 1 (5alpha-R1), sulfotransferase 2B1 (SULT2B1) and some GABA-A receptor subunits (alpha4, beta1) while in the CN, upregulation of 3alpha-hydroxysteroid dehydrogenase type 3 (3alpha-HSD3) and alpha4 GABA-A receptor subunit (22-fold) was observed. No significant differences were found in the PU. These data imply an involvement of pregnane steroids and changes in GABAergic neurotransmission in the neurodegenerative process and suggest that neurosteroids may deserve further investigation as potential therapeutic agents in PD.
Luchetti
Sabina
S
Netherlands Institute for Neuroscience, Royal Netherlands Academy of Arts and Sciences, Amsterdam, The Netherlands. s.luchetti@nin.knaw.nl
Bossers
Koen
K
Frajese
Giovanni Vanni
GV
Swaab
Dick F
DF
D000368:Aged; D000369:Aged, 80 and over; D016022:Case-Control Studies; D002421:Caudate Nucleus / Q000378:metabolism*; D004268:DNA-Binding Proteins / Q000235:genetics / Q000378:metabolism; D005260:Female; D005786:Gene Expression Regulation / Q000502:physiology; D006801:Humans; D008297:Male; D009434:Neural Pathways / Q000378:metabolism; D018377:Neurotransmitter Agents / Q000378:metabolism*; D010300:Parkinson Disease / Q000473:pathology*; D012333:RNA, Messenger / Q000378:metabolism; D018079:Receptors, GABA / Q000235:genetics / Q000378:metabolism; D013378:Substantia Nigra / Q000378:metabolism*; D015238:Sulfotransferases / Q000235:genetics / Q000378:metabolism
D004268:DNA-Binding Proteins; D018377:Neurotransmitter Agents; D012333:RNA, Messenger; D018079:Receptors, GABA; D015238:Sulfotransferases; C433248:SULT2B1 protein, human
Brain Res. 1997 Aug 1;764(1-2):173-8
9295207
Brain Res. 1987 Feb 24;404(1-2):355-60
3032339
Brain Res. 1996 Nov 25;741(1-2):142-52
9001716
Mov Disord. 2003 Mar;18(3):241-53
12621627
Brain Pathol. 2009 Jan;19(1):91-107
18462474
Eur J Pharmacol. 1999 Jun 30;375(1-3):225-35
10443579
Restor Neurol Neurosci. 2004;22(1):19-31
15096691
Neuroendocrinology. 2006;84(4):275-9
17124377
Neurosci Lett. 2002 Aug 2;328(1):33-6
12123853
Pharmacol Biochem Behav. 2009 Jun;92(4):608-13
19268499
Genome Biol. 2002 Jun 18;3(7):RESEARCH0034
12184808
Ann Neurol. 1986 Jul;20(1):26-31
2874765
Neuroendocrinology. 2003 Apr;77(4):223-31
12766322
Synapse. 2000 Sep 15;37(4):245-51
10891861
Mol Cell Endocrinol. 2008 Aug 13;290(1-2):60-9
18515001
J Neurosci. 2009 Feb 11;29(6):1755-65
19211882
Neurosci Lett. 1988 Nov 22;94(1-2):182-6
3241667
Science. 1986 May 23;232(4753):1004-7
2422758
J Neuroendocrinol. 2004 Jan;16(1):58-63
14962077
Int Rev Neurobiol. 2001;46:1-32
11599297
Eur J Neurosci. 2002 Aug;16(3):445-53
12193187
Mol Pharmacol. 2000 Jun;57(6):1262-70
10825399
Pharmacol Ther. 2007 Oct;116(1):77-106
17659348
Nature. 1998 Apr 30;392(6679):926-30
9582073
Neurol Sci. 2003 Oct;24(3):172-3
14598072
Front Neuroendocrinol. 2000 Jan;21(1):1-56
10662535
Neurobiol Aging. 1995 May-Jun;16(3):271-8; discussion 278-84
7566337
Pharmacol Biochem Behav. 2006 Aug;84(4):545-54
16914187
Neurobiol Aging. 2003 Mar-Apr;24(2):197-211
12498954
J Neurosci Methods. 2006 Jun 15;153(2):290-8
16378642
J Mol Neurosci. 2008 Mar;34(3):193-200
18219447
Brain Res. 1990 Oct 8;529(1-2):57-78
1704287
Int Rev Neurobiol. 2001;46:207-41
11599301
J Neurochem. 1983 Apr;40(4):1120-3
6131932
Mol Pharmacol. 1991 Sep;40(3):333-6
1654510
Eur J Neurosci. 2005 May;21(9):2329-35
15932592
Front Neuroendocrinol. 2009 Aug;30(3):259-301
19505496
Front Neuroendocrinol. 2009 Jul;30(2):142-57
19410597
Neurotherapeutics. 2007 Jan;4(1):102-5
17199022
Nucleic Acids Res. 2001 May 1;29(9):e45
11328886
Neuroscience. 2004;123(2):349-59
14698743
Mol Aspects Med. 2006 Apr-Jun;27(2-3):126-39
16469371
Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3202-7
14973190
J Neurotrauma. 2005 Jan;22(1):106-18
15665606
J Neurosci. 2005 May 11;25(19):4706-18
15888646
Synapse. 2001 Aug;41(2):131-8
11400179
Cell Mol Life Sci. 2008 Mar;65(5):777-97
18038216
J Neurosci. 2004 Nov 17;24(46):10318-25
15548645
Neuroscience. 2005;131(2):397-405
15708482
Biol Psychiatry. 2004 Feb 15;55(4):346-52
14960286
Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1852-7
9465106
J Pharmacol Exp Ther. 1997 Mar;280(3):1284-95
9067315
J Neurochem. 2003 Aug;86(4):848-59
12887683
Synapse. 2003 Jan;47(1):10-4
12422368
Eur J Endocrinol. 2001 Dec;145(6):669-79
11720889
Brain Res Rev. 2008 Mar;57(2):410-20
17629950
Epilepsia. 2007 Oct;48(10):1870-4
17634060
Neuroreport. 2000 Feb 7;11(2):343-6
10674483
Horm Behav. 2010 Jan;57(1):23-34
19538962
Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13284-9
9789080
Brain Res. 2001 Aug 10;910(1-2):55-66
11489254
Nat Rev Neurosci. 2005 Mar;6(3):215-29
15738957
Curr Alzheimer Res. 2007 Dec;4(5):510-7
18220513